EUCTR2015-002094-38-GB进行中（未招募）1 期
The Effect of an SGLT2 inhibitor on Glucose Flux, Lipolysis and Ketogenesis following insulin withdrawal in people with absolute or relative endogenous insulin deficiency - SIDS version
niversity of Leicester0 个研究点目标入组 30 人开始时间: 2015年9月18日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Able in the opinion of the investigator, and willing to give informed consent obtained before any trial-related activities.
- •Type 1 diabetes or type 3c (chronic pancreatitis or undergone pancreatic surgery) according to clinical judgment.
- •Duration of type 1 or type 3c diabetes (chronic pancreatitis or undergone pancreatic surgery) greater than 12 months.
- •Current treatment basal bolus or insulin pump therapy
- •Aged 18 years or over
- •BMI of less than 35.
- •HbA1c of greater or equal to 6.5% and less than 9%.
- •Able and willing to complete the trial.
- •Patients who are or who have previously been involved in research are eligible provided they have not received an investigational drug within one month of entry into the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Participants over 65
- •Participants who cannot adequately understand verbal and / or written explanations given in English
- •Proliferative retinopathy that has required acute treatment within last three months.
- •LADA –latent autoimmune diabetes in adults due to differing nature of the illness/Type 1
- •Confirmed excessive and compulsive drinking of alcohol i.e. alcohol abuse as determined from GP medical notes by the Fast Alcohol Screening Test (FAST) or history of previous alcohol abuse
- •Restricted food intake (e.g. on VLC diets) - as this depletes the person of calories and may affect your data. Consider excluding Individuals on a severe calorie restricted diet <800cals/day. Determined by history
- •Diagnosis of osteoporosis confimed by DEXA scan.
- •Moderate to severe renal impairment (creatinine clearance [CrCl] < 60 ml/min or estimated glomerular filtration rate [eGFR] < 60 ml/min/1.73 m2.
- •History of unstable or rapidly progressing renal disease
- •Severe hepatic insufficiency / and or significant abnormal liver function defines as aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and / or alanine aminotransferase (ALT) > 3ULN.
- •Positive serologic evidence of current infectious liver disease including Hepatitis B viral antibody IGM, Hepatitis B surface antigen and Hepatitis C virus antibody.
- •Congestive heart failure defined as New York Heart Association (NYHA) class III and IV, unstable or acute congestive heart failure. Note: eligible patients with congestive heart failure, especially
- •Uncontrolled cardiac arrhythmias.
- •Uncontrolled hypertension. (BP greater than 160/90).
- •Mental incapacity.
- •Pregnancy or breast feeding women
- •Those of child-bearing potential not taking adequate contraception precautions. Adequate protection is defined as barrier protection, oral contraceptive pill or intrauterine device
- •Volume depleted patients, patients at risk of volume depleting due to co-existing conditions or concomitant medications, such as loop diuretics should have careful monitoring of their volume status
- •History of unstable angina.
- •Recent Cardiovascular Events in a patient:
- •Acute Coronary Syndrome (ACS) within 2 months prior to enrolment
- •Hospitalisation for unstable angina or acute myocardial infarction within 2 months prior to enrolment
- •Acute Stroke or TIA within two months prior to enrolment
- •Less than two months post coronary artery revascularization
- •History of diabetic ketoacidosis (DKA) requiring medical intervention (e.g. Accident and Emergency and/or hospitalisation) within 1 month prior to the Screening visit.
- •Known or suspected allergy to trial products.
- •Known lactose-intolerant individuals.
- •Any other medical or psychological conditions that would interfere with the trial participation.
研究者
相似试验
进行中（未招募）
1 期
The effect of SGLT2 inhibitors in people with type 2 diabetesEUCTR2016-004878-17-GBniversity of Leicester18
尚未招募
不适用
Effects of a SGLT2 inhibitor on glucose metabolism and body composition in patients with type 2 diabetesType 2 diabetes mellitusJPRN-UMIN000015402Department of Diabetes and Endocrinology Kobe City Medical Center General Hospital30
已完成
不适用
The Effect of SGLT2 inhibitors on blood glucose variability in patients with type 1 diabetestype 1 diabetes mellitusJPRN-UMIN000039361Hokkaido University Hospital30
已完成
不适用
Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors on metabolic parameters in patients with type 2 diabetes: A chart-based analysistype 2 diabetesJPRN-UMIN000020314ational Center for Global Health and Medicine Kohnodai Hospital75
招募中
不适用
Effects of a SGLT2 Inhibitor in type 2 Diabetes Mellitustype 2 Diabetes MellitusJPRN-UMIN000017461ephrology, endocrinology and vascular medicine at Tohoku University Hospital60